screen_shot_2014-04-30_at_08

Lonza makes change at the top

pharmafile | April 30, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Lonza, funk 

Swiss pharma supplier firm Lonza has confirmed a leadership change as its chief operating officer (COO) leaves. 

Marc Funk has been appointed COO of the Pharma&Biotech segment as Stephan Kutzer has decided to depart from the company.  

As of 1 July Funk will take on the full leadership role for its Pharma&Biotech unit from Kutzer, who will ensure that the handover is completed and is to conduct additional transitional activities.  

Advertisement

Lonza’s chief executive Richard Ridinger says: “Marc has been the Group’s chief legal officer and board secretary since 2009 and a member of the EC since 2012. He has already successfully managed operational and commercial projects in the Pharma&Biotech network and has been responsible for Global Quality in Pharma&Biotech for more than a year.

“Also he has broad experience in this field as he was formerly co-founder of a biotech research company and has had a strong commercial focus in other parts of his career. I am confident he’ll be able to steer that segment through this critical growth phase and into the future.” 

Related Content

Lonza to acquire biologics site in Vacaville, US from Roche for $1.2bn

Lonza has announced that it has signed an agreement to acquire the Genentech large-scale biologics …

Lonza to acquire Synaffix to strengthen ADC development

Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has …

moderna_norwood_plant

Moderna submits BLA with FDA for COVID vaccine

Moderna has initiated the rolling submission process with the FDA for a Biologics License Application …

The Gateway to Local Adoption Series

Latest content